Merck & Co., Inc., is committed to make pediatric Raltegravir available at no profit in low income, least developed countries and across Sub-saharan African countries until generics are available.

-

Merck & Co., Inc., confirmed (in a meeting with PEPFAR) their intention to provide paediatric drugs at access pricing until generics are available, and potentially beyond in LMIC.

-

-

-

-

-

-

-

-

-